본문 바로가기
KERD
논문KCI 등재

Harnessing the Power of IL-7 to Boost T Cell Immunity in Experimental and Clinical Immunotherapies

Seung-Woo Lee|Young Chul Sung|Jung-Hyun Park|Donghoon Choi|Changhyung Lee
대한면역학회 (The Korean Association of Immunologists)|2024.02|Immune Network|제24권 제1호|pp. 1-21|DOI 10.4110/in.2024.24.e9

1

조회

0

다운로드

1

인용

0

참고문헌

키워드

Clinical trialTumorCytokineInflammationImmune system diseases

초록

The cytokine IL-7 plays critical and nonredundant roles in T cell immunity so that the abundance and availability of IL-7 act as key regulatory mechanisms in T cell immunity. Importantly, IL-7 is not produced by T cells themselves but primarily by non-lymphoid lineage stromal cells and epithelial cells that are limited in their numbers. Thus, T cells depend on cell extrinsic IL-7, and the amount of in vivo IL-7 is considered a major factor in maximizing and maintaining the number of T cells in peripheral tissues. Moreover, IL-7 provides metabolic cues and promotes the survival of both naïve and memory T cells. Thus, IL-7 is also essential for the functional fitness of T cells. In this regard, there has been an extensive effort trying to increase the protein abundance of IL-7 in vivo, with the aim to augment T cell immunity and harness T cell functions in anti-tumor responses. Such approaches started under experimental animal models, but they recently culminated into clinical studies, with striking effects in re-establishing T cell immunity in immunocompromised patients, as well as boosting anti-tumor effects. Depending on the design, glycosylation, and the structure of recombinantly engineered IL-7 proteins and their mimetics, recombinant IL-7 molecules have shown dramatic differences in their stability, efficacy, cellular effects, and overall immune functions. The current review is aimed to summarize the past and present efforts in the field that led to clinical trials, and to highlight the therapeutical significance of IL-7 biology as a master regulator of T cell immunity.

Abstract

The cytokine IL-7 plays critical and nonredundant roles in T cell immunity so that the abundance and availability of IL-7 act as key regulatory mechanisms in T cell immunity. Importantly, IL-7 is not produced by T cells themselves but primarily by non-lymphoid lineage stromal cells and epithelial cells that are limited in their numbers. Thus, T cells depend on cell extrinsic IL-7, and the amount of in vivo IL-7 is considered a major factor in maximizing and maintaining the number of T cells in peripheral tissues. Moreover, IL-7 provides metabolic cues and promotes the survival of both naïve and memory T cells. Thus, IL-7 is also essential for the functional fitness of T cells. In this regard, there has been an extensive effort trying to increase the protein abundance of IL-7 in vivo, with the aim to augment T cell immunity and harness T cell functions in anti-tumor responses. Such approaches started under experimental animal models, but they recently culminated into clinical studies, with striking effects in re-establishing T cell immunity in immunocompromised patients, as well as boosting anti-tumor effects. Depending on the design, glycosylation, and the structure of recombinantly engineered IL-7 proteins and their mimetics, recombinant IL-7 molecules have shown dramatic differences in their stability, efficacy, cellular effects, and overall immune functions. The current review is aimed to summarize the past and present efforts in the field that led to clinical trials, and to highlight the therapeutical significance of IL-7 biology as a master regulator of T cell immunity.

참고문헌 (105)

  1. Notarangelo LD, "Of genes and phenotypes : the immunological and molecular spectrum of combined immune deficiency. Defects of the gamma(c)-JAK3 signaling pathway as a model", Immunol Rev, 178, pp.39~48 (2000)
  2. Leonard WJ, "The γc family of cytokines : basic biology to therapeutic ramifications", Immunity, 50, pp.832~850 (2019)
  3. Waickman AT, "The common γ-chain cytokine receptor : tricks-and-treats for T cells", Cell Mol Life Sci, 73, pp.253~269 (2016)
  4. Fontenot JD, "A function for interleukin 2 in Foxp3-expressing regulatory T cells", Nat Immunol, 6, pp.1142~1151 (2005)
  5. Won HY, "Proinflammatory IFNγ is produced by but not required for the generation of Eomes+ thymic innate CD8 T cells", Cells, 12, pp.2433~ (2023)
  6. Gordy LE, "IL-15 regulates homeostasis and terminal maturation of NKT cells", J Immunol, 187, pp.6335~6345 (2011)
  7. Maeurer MJ, "Interleukin-7(IL-7)knockout mice. Implications for lymphopoiesis and organ-specific immunity", Int Rev Immunol, 16, pp.309~322 (1998)
  8. Winer H, "IL-7 : comprehensive review", Cytokine, 160, pp.156049~ (2022)
  9. Corcoran AE, "Impaired immunoglobulin gene rearrangement in mice lacking the IL-7 receptor", Nature, 391, pp.904~907 (1998)
  10. Kang J, "Defective development of gamma", delta T cells in interleukin 7 receptor-deficient mice is due to impaired expression of T cell receptor gamma genes, 1999, pp.190, 973~982
  11. Schlissel MS, "The interleukin 7 receptor is required for T cell receptor gamma locus accessibility to the V(D)J recombinase", J Exp Med, 191, pp.1045~1050 (2000)
  12. Kim GY, "Seeing is believing : illuminating the source of in vivo interleukin-7", Immune Netw, 11, pp.1~10 (2011)
  13. Peschon JJ, "Early lymphocyte expansion is severely impaired in interleukin 7 receptor-deficient mice", J Exp Med, 180, pp.1955~1960 (1994)
  14. von Freeden-Jeffry U, "Lymphopenia in interleukin(IL)-7 gene-deleted mice identifies IL-7 as a nonredundant cytokine", J Exp Med, 181, pp.1519~1526 (1995)
  15. Kang J, "Evidence that γδ versus αβ T cell fate determination is initiated independently of T cell receptor signaling", J Exp Med, 193, pp.689~698 (2001)
  16. McCaughtry TM, "Conditional deletion of cytokine receptor chains reveals that IL-7 and IL-15 specify CD8 cytotoxic lineage fate in the thymus", J Exp Med, 209, pp.2263~2276 (2012)
  17. Park JH, "Signaling by intrathymic cytokines, not T cell antigen receptors, specifies CD8 lineage choice and promotes the differentiation of cytotoxic-lineage T cells", Nat Immunol, 11, pp.257~264 (2010)
  18. Egawa T, "Runx and ThPOK : a balancing act to regulate thymocyte lineage commitment", J Cell Biochem, 107, pp.1037~1045 (2009)
  19. Luckey MA, "The transcription factor ThPOK suppresses Runx3 and imposes CD4+ lineage fate by inducing the SOCS suppressors of cytokine signaling", Nat Immunol, 15, pp.638~645 (2014)
  20. Vogt TK, "Novel function for interleukin-7 in dendritic cell development", Blood, 113, pp.3961~3968 (2009)
  21. Vonarbourg C, "Multifaceted roles of interleukin-7 signaling for the development and function of innate lymphoid cells", Semin Immunol, 24, pp.165~174 (2012)
  22. Mazzucchelli R, "Interleukin-7 receptor expression : intelligent design", Nat Rev Immunol, 7, pp.144~154 (2007)
  23. Park JH, "Suppression of IL7Ralpha transcription by IL-7 and other prosurvival cytokines : a novel mechanism for maximizing IL-7-dependent T cell survival", Immunity, 21, pp.289~302 (2004)
  24. Bradley LM, "IL-7 : maintaining T-cell memory and achieving homeostasis", Trends Immunol, 26, pp.172~176 (2005)
  25. Yu Q, "Cytokine signal transduction is suppressed in preselection double-positive thymocytes and restored by positive selection", J Exp Med, 203, pp.165~175 (2006)
  26. Kimura MY, "IL-7 signaling must be intermittent, not continuous, during CD8+ T cell homeostasis to promote cell survival instead of cell death", Nat Immunol, 14, pp.143~151 (2013)
  27. Hong C, "Activated T cells secrete an alternatively spliced form of common γ-chain that inhibits cytokine signaling and exacerbates inflammation", Immunity, 40, pp.910~923 (2014)
  28. Lundström W, "Soluble IL7Rα potentiates IL-7 bioactivity and promotes autoimmunity", Proc Natl Acad Sci U S A, 110, pp.E1761~ (2013)
  29. Won HY, "Identification of alternatively spliced Il7r transcripts in mouse T cells that encode soluble IL-7Rα", Cell Mol Immunol, 17, pp.1284~1286 (2020)
  30. Ghazawi FM, "Suppressor of cytokine signaling(SOCS)proteins are induced by IL-7 and target surface CD127 protein for degradation in human CD8 T cells", Cell Immunol, 306-307, pp.41~52 (2016)
  31. Bosco N, "Effects of increasing IL-7 availability on lymphocytes during and after lymphopenia-induced proliferation", J Immunol, 175, pp.162~170 (2005)
  32. Mertsching E, "Phenotypic and functional analysis of B lymphopoiesis in interleukin-7-transgenic mice : expansion of pro", pre-B cell number and persistence of B lymphocyte development in lymph nodes and spleen, 1996, pp.26, 28~33
  33. Watanabe M, "Mucosal IL-7-mediated immune responses in chronic colitis-IL-7 transgenic mouse model", Immunol Res, 20, pp.251~259 (1999)
  34. Schreiber M, "Inducible IL-7 hyperexpression influences lymphocyte homeostasis and function and increases allograft rejection", Front Immunol, 10, pp.742~ (2019)
  35. Martin CE, "Interleukin-7 availability is maintained by a hematopoietic cytokine sink comprising innate lymphoid cells and T cells", Immunity, 47, pp.171~182 (2017)
  36. Williams KM, "T cell immune reconstitution following lymphodepletion", Semin Immunol, 19, pp.318~330 (2007)
  37. den Braber I, "Maintenance of peripheral naive T cells is sustained by thymus output in mice but not humans", Immunity, 36, pp.288~297 (2012)
  38. Martin CE, "IL-7", anti-IL-7 mAb complexes augment cytokine potency in mice through association with IgG-Fc and by competition with IL-7R, 2013, pp.121, 4484~4492
  39. Pandit H, "Step-dose IL-7 treatment promotes systemic expansion of T cells and alters immune cell landscape in blood and lymph nodes", iScience, 26, pp.105929~ (2023)
  40. Park JY, "In vivo availability of the cytokine IL-7 constrains the survival and homeostasis of peripheral iNKT cells", Cell Reports, 38, pp.110219~ (2022)
  41. Sportès C, "Phase I study of recombinant human interleukin-7 administration in subjects with refractory malignancy", Clin Cancer Res, 16, pp.727~735 (2010)
  42. ElKassar N, "An overview of IL-7 biology and its use in immunotherapy", J Immunotoxicol, 7, pp.1~7 (2010)
  43. Surh CD, "Homeostasis of naive and memory T cells", Immunity, 29, pp.848~862 (2008)
  44. Wolfarth AA, "Advancements of common gamma-chain family cytokines in cancer immunotherapy", Immune Netw, 22, pp.e5~ (2022)
  45. Barata JT, "Flip the coin : IL-7 and IL-7R in health and disease", Nat Immunol, 20, pp.1584~1593 (2019)
  46. Kim JH, "Cancer immunotherapy with T-cell targeting cytokines : IL-2 and IL-7", BMB Rep, 54, pp.21~30 (2021)
  47. Xu X, "Newcastle disease virus co-expressing interleukin 7 and interleukin 15 modified tumor cells as a vaccine for cancer immunotherapy", Cancer Sci, 109, pp.279~288 (2018)
  48. Sharma S, "Interleukin-7 gene-modified dendritic cells reduce pulmonary tumor burden in spontaneous murine bronchoalveolar cell carcinoma", Hum Gene Ther, 14, pp.1511~1524 (2003)
  49. Li B, "Recombinant IL-7 enhances the potency of GM-CSF-secreting tumor cell immunotherapy", Clin Immunol, 123, pp.155~165 (2007)
  50. Colombetti S, "IL-7 adjuvant treatment enhances long-term tumor-antigen-specific CD8+ T-cell responses after immunization with recombinant lentivector", Blood, 113, pp.6629~6637 (2009)
  51. Pellegrini M, "Adjuvant IL-7 antagonizes multiple cellular and molecular inhibitory networks to enhance immunotherapies", Nat Med, 15, pp.528~536 (2009)
  52. Boyman O, "IL-7", anti-IL-7 mAb complexes restore T cell development and induce homeostatic T cell expansion without lymphopenia, 2008, pp.180, 7265~7275
  53. Nam HJ, "Marked enhancement of antigen-specific T-cell responses by IL-7-fused nonlytic, but not lytic, Fc as a genetic adjuvant", Eur J Immunol, 40, pp.351~358 (2010)
  54. Choi YW, "Intravaginal administration of Fc-fused IL7 suppresses the cervicovaginal tumor by recruiting HPV DNA vaccine-induced CD8 T cells", Clin Cancer Res, 22, pp.5898~5908 (2016)
  55. Im SJ, "Natural form of noncytolytic flexible human Fc as a long-acting carrier of agonistic ligand, erythropoietin", PLoS One, 6, pp.e24574~ (2011)
  56. Shin H, "A vaccine strategy that protects against genital herpes by establishing local memory T cells", Nature, 491, pp.463~467 (2012)
  57. Kim JH, "Hybrid Fc-fused interleukin-7 induces an inflamed tumor microenvironment and improves the efficacy of cancer immunotherapy", Clin Transl Immunology, 9, pp.e1168~ (2020)
  58. Campian JL, "Long-acting recombinant human interleukin-7, NT-I7, increases cytotoxic CD8 T cells and enhances survival in mouse glioma models", Clin Cancer Res, 28, pp.1229~1239 (2022)
  59. Dangaj D, "Cooperation between constitutive and inducible chemokines enables T cell engraftment and immune attack in solid tumors", Cancer Cell, 35, pp.885~900 (2019)
  60. Kim MY, "A long-acting interleukin-7, rhIL-7-hyFc, enhances CAR T cell expansion, persistence, and anti-tumor activity", Nat Commun, 13, pp.3296~ (2022)
  61. Grossman SA, "Survival in Patients with severe lymphopenia following treatment with radiation and chemotherapy for newly diagnosed solid tumors", J Natl Compr Canc Netw, 13, pp.1225~1231 (2015)
  62. Ding ZC, "Adjuvant IL-7 potentiates adoptive T cell therapy by amplifying and sustaining polyfunctional antitumor CD4+ T cells", Sci Rep, 7, pp.12168~ (2017)
  63. Yu EM, "IL7-Fc enhances the efficacy of adoptive T cell therapy under lymphopenic conditions in a murine melanoma model", Cells, 10, pp.2018~ (2021)
  64. Singh N, "Synthetic manipulation of the cancer-immunity cycle : CAR-T cell therapy", Immunity, 56, pp.2296~2310 (2023)
  65. Adachi K, "IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor", Nat Biotechnol, 36, pp.346~351 (2018)
  66. He C, "Co-expression of IL-7 improves NKG2D-based CAR T cell therapy on prostate cancer by enhancing the expansion and inhibiting the apoptosis and exhaustion", Cancers(Basel), 12, pp.1969~ (2020)
  67. Trédan O, "ELYPSE-7 : a randomized placebo-controlled phase IIa trial with CYT107 exploring the restoration of CD4+ lymphocyte count in lymphopenic metastatic breast cancer patients", Ann Oncol, 26, pp.1353~1362 (2015)
  68. Kudling TV, "Local delivery of interleukin 7 with an oncolytic adenovirus activates tumor-infiltrating lymphocytes and causes tumor regression", OncoImmunology, 11, pp.2096572~ (2022)
  69. Nakao S, "Intratumoral expression of IL-7 and IL-12 using an oncolytic virus increases systemic sensitivity to immune checkpoint blockade", Sci Transl Med, 12, pp.eaax7992~ (2020)
  70. Huang J, "Interleukin-7-loaded oncolytic adenovirus improves CAR-T cell therapy for glioblastoma", Cancer Immunol Immunother, 70, pp.2453~2465 (2021)
  71. Fry TJ, "IL-7 therapy dramatically alters peripheral T-cell homeostasis in normal and SIV-infected nonhuman primates", Blood, 101, pp.2294~2299 (2003)
  72. Vassena L, "Treatment with IL-7 prevents the decline of circulating CD4+ T cells during the acute phase of SIV infection in rhesus macaques", PLoS Pathog, 8, pp.e1002636~ (2012)
  73. Nanjappa SG, "Immunotherapeutic effects of IL-7 during a chronic viral infection in mice", Blood, 117, pp.5123~5132 (2011)
  74. Pellegrini M, "IL-7 engages multiple mechanisms to overcome chronic viral infection and limit organ pathology", Cell, 144, pp.601~613 (2011)
  75. Kang MC, "Intranasal Introduction of Fc-Fused Interleukin-7 Provides Long-Lasting Prophylaxis against Lethal Influenza Virus Infection", J Virol, 90, pp.2273~2284 (2016)
  76. Kang MC, "Plasmacytoid dendritic cells contribute to the protective immunity induced by intranasal treatment with Fc-fused interleukin-7 against lethal influenza virus infection", Immune Netw, 17, pp.343~351 (2017)
  77. Kwon DI, "Fc-fused IL-7 provides broad antiviral effects against respiratory virus infections through IL-17A-producing pulmonary innate-like T cells", Cell Rep Med, 5, pp.101362~ (2024)
  78. Hassane M, "Interleukin-7 protects against bacterial respiratory infection by promoting IL-17A-producing innate T-cell response", Mucosal Immunol, 13, pp.128~139 (2020)
  79. Seo YB, "Crucial roles of interleukin-7 in the development of T follicular helper cells and in the induction of humoral immunity", J Virol, 88, pp.8998~9009 (2014)
  80. Logerot S, "IL-7-adjuvanted vaginal vaccine elicits strong mucosal immune responses in non-human primates", Front Immunol, 12, pp.614115~ (2021)
  81. Alpdogan O, "Administration of interleukin-7 after allogeneic bone marrow transplantation improves immune reconstitution without aggravating graft-versus-host disease", Blood, 98, pp.2256~2265 (2001)
  82. Storek J, "Interleukin-7 improves CD4 T-cell reconstitution after autologous CD34 cell transplantation in monkeys", Blood, 101, pp.4209~4218 (2003)
  83. Grzegorzewski K, "Administration of recombinant human interleukin-7 to mice induces the exportation of myeloid progenitor cells from the bone marrow to peripheral sites", Blood, 83, pp.377~385 (1994)
  84. Grzegorzewski KJ, "Mobilization of long-term reconstituting hematopoietic stem cells in mice by recombinant human interleukin 7", J Exp Med, 181, pp.369~374 (1995)
  85. Kim S, "Fc-fused IL-7 mobilizes long-term HSCs in a pro-B cell-dependent manner and synergizes with G-CSF and AMD3100", Leukemia, 35, pp.3030~3034 (2021)
  86. Schultze JL, "Emerging principles in myelopoiesis at homeostasis and during infection and inflammation", Immunity, 50, pp.288~301 (2019)
  87. Sportès C, "Administration of rhIL-7 in humans increases in vivo TCR repertoire diversity by preferential expansion of naive T cell subsets", J Exp Med, 205, pp.1701~1714 (2008)
  88. Rosenberg SA, "IL-7 administration to humans leads to expansion of CD8+ and CD4+ cells but a relative decrease of CD4+ T-regulatory cells", J Immunother, 29, pp.313~319 (2006)
  89. Levy Y, "Enhanced T cell recovery in HIV-1-infected adults through IL-7 treatment", J Clin Invest, 119, pp.997~1007 (2009)
  90. Sereti I, "IL-7 administration drives T cell-cycle entry and expansion in HIV-1 infection", Blood, 113, pp.6304~6314 (2009)
  91. Perales MA, "Recombinant human interleukin-7(CYT107)promotes T-cell recovery after allogeneic stem cell transplantation", Blood, 120, pp.4882~4891 (2012)
  92. Lévy Y, "Effects of recombinant human interleukin 7 on T-cell recovery and thymic output in HIV-infected patients receiving antiretroviral therapy : results of a phase I", IIa randomized, placebo-controlled, multicenter study, 2012, pp.55, 291~300
  93. Katlama C, "Treatment intensification followed by interleukin-7 reactivates HIV without reducing total HIV DNA : a randomized trial", AIDS, 30, pp.221~230 (2016)
  94. Sereti I, "Decreases in colonic and systemic inflammation in chronic HIV infection after IL-7 administration", PLoS Pathog, 10, pp.e1003890~ (2014)
  95. Thiébaut R, "Repeated cycles of recombinant human interleukin 7 in HIV-infected patients with low CD4 T-cell reconstitution on antiretroviral therapy : results of 2 phase II multicenter studies", Clin Infect Dis, 62, pp.1178~1185 (2016)
  96. Merchant MS, "Adjuvant immunotherapy to improve outcome in high-risk pediatric sarcomas", Clin Cancer Res, 22, pp.3182~3191 (2016)
  97. Pachynski RK, "IL-7 expands lymphocyte populations and enhances immune responses to sipuleucel-T in patients with metastatic castration-resistant prostate cancer(mCRPC)", J Immunother Cancer, 9, pp.e002903~ (2021)
  98. Sheikh V, "Administration of interleukin-7 increases CD4 T cells in idiopathic CD4 lymphocytopenia", Blood, 127, pp.977~988 (2016)
  99. Miskin DP, "Interleukin-7 treatment of PML in a patient with idiopathic lymphocytopenia", Neurol Neuroimmunol Neuroinflamm, 3, pp.e213~ (2016)
  100. Alstadhaug KB, "Treatment of progressive multifocal leukoencephalopathy with interleukin 7", JAMA Neurol, 71, pp.1030~1035 (2014)
  101. Sospedra M, "Treating progressive multifocal leukoencephalopathy with interleukin 7 and vaccination with JC virus capsid protein VP1", Clin Infect Dis, 59, pp.1588~1592 (2014)
  102. Francois B, "Interleukin-7 restores lymphocytes in septic shock : the IRIS-7 randomized clinical trial", JCI insight, 3, pp.e98960~ (2018)
  103. Laterre PF, "Association of interleukin 7 immunotherapy with lymphocyte counts among patients with severe coronavirus disease 2019(COVID-19)", JAMA Netw Open, 3, pp.e2016485~ (2020)
  104. Daix T, "Intravenously administered interleukin-7 to reverse lymphopenia in patients with septic shock : a double-blind, randomized, placebo-controlled trial", Ann Intensive Care, 13, pp.17~ (2023)
  105. Lee SW, "hIL-7-hyFc, a long-acting IL-7, increased absolute lymphocyte count in healthy subjects", Clin Transl Sci, 13, pp.1161~1169 (2020)

관련 논문AI추천

Seeing is Believing: Illuminating the Source of In Vivo Interleukin-7박정현, 홍창완, Grace Yoonhee Kim대한면역학회 · Immune Network2011 · 제11권 제1호Cancer immunotherapy with T-cell targeting cytokines: IL-2 and IL-7김지혜, 이건주, Seung-Woo Lee생화학분자생물학회 · BMB Reports2021 · 제54권 제1호Advancements of Common Gamma-Chain Family Cytokines in Cancer Immunotherapy이병하, Dhar Swati, Ezeanya Ugonna I., Ferrando-Martínez Sara, Goon Jack B., Wolfarth Alexandra A.대한면역학회 · Immune Network2022 · 제22권 제1호Optimising IL-2 for Cancer ImmunotherapyJonathan Sprent, Onur Boyman대한면역학회 · Immune Network2024 · 제24권 제1호Interleukin-7 Receptor is Indispensable for Proliferation and Survival in Thymic γδT Cell Development고성희, 김경제, 김동현, 김홍숙, 예상규, 윤병학, 이광호, 정명희, 정주은, 최은영대한면역학회 · Immune Network2005 · 제5권 제1호IL-15 in T-Cell Responses and Immunopathogenesis박수형, Eui-Cheol Shin, Hoyoung Lee대한면역학회 · Immune Network2024 · 제24권 제1호

이 간행물의 다른 논문 (9건)

IL-15 in T-Cell Responses and Immunopathogenesis박수형, Hoyoung Lee, Eui-Cheol Shinpp. 1-18Cytokines in Follicular Helper T Cell Biology in Physiologic and Pathologic ConditionsJinyong Choi, Shane Crotty, Youn Soo Choipp. 1-17TNF in Human Tuberculosis: A Double-Edged SwordJin Kyung Kim, In Soo Kim, Jae-Min Yuk, Eun-Kyeong Jopp. 1-19Interleukin-18 Binding Protein (IL-18BP): A Long Journey From Discovery to Clinical ApplicationSoohyun Kim, Hyeon Yu, Tania Azam, Charles A. Dinarellopp. 1-6Cytokines and Immune Disorders: Illuminating Cytokines as Hubs Within the Immune Network이종길, 이승우pp. 1-3
원문 보기